"instanceType","uuid:ID","id","rationale","versionIdentifier"
"StudyVersion","b4a1f828-a9e6-4709-a60e-53fb43e0878d","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2"
